Press Releases

Press Releases

    Date Title View
    11/23/20
    Summary ToggleHorizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
    PDF Version
    11/17/20
    Summary ToggleNational Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation
    PDF Version
    11/16/20
    Summary ToggleFirst Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease
    PDF Version
    11/13/20
    Summary ToggleNew Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration
    PDF Version
    11/13/20
    Summary ToggleHorizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala
    PDF Version
    11/12/20
    Summary ToggleHorizon Therapeutics plc to Participate in Upcoming Investor Conferences
    PDF Version
    11/02/20
    Summary ToggleHigher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
    PDF Version
    11/02/20
    Summary ToggleHorizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance
    11/02/20
    Summary ToggleHorizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
    PDF Version
    10/30/20
    Summary ToggleChicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
    PDF Version
    Displaying 1 - 10 of 544 results